Lipella Pharmaceuticals Inc. (LIPO) vs Virax Biolabs Group Limited (VRAX)

Lipella Pharmaceuticals Inc. and Virax Biolabs Group Limited are both Biotechnology companies. Lipella Pharmaceuticals Inc. and Virax Biolabs Group Limited are of similar size ($3.4M and $3.3M). Across the 9 metrics below, Lipella Pharmaceuticals Inc. leads on 5 and Virax Biolabs Group Limited on 4.

Valuation

Metric LIPO VRAX Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.31 0.86 0.74
EV/Sales (3.61) n/m 10.73
Earnings yield 0.00% (222.08%) (28.84%)
Free cash flow yield 0.00% 0.00% (23.03%)

Profitability

Metric LIPO VRAX Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (361.77%) 0.00% (57.72%)
Return on assets (236.36%) 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LIPO VRAX Biotechnology median
Revenue growth (TTM) (7.29%) — 5.64%
EPS growth (last fiscal year) 22.24% 68.79% —
Revenue growth, 5-year CAGR (5.04%) (36.88%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LIPO VRAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.24 9.97 4.73
Net debt to EBITDA 0.43 1.08 0.96

Dividend

Metric LIPO VRAX Biotechnology median
Dividend yield — — 2.10%
Payout ratio — — 0.00

Size

Metric LIPO VRAX Biotechnology median
Market cap 3.39m 3.28m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack